home / stock / gmab / gmab news


GMAB News and Press, Genmab A/S From 11/07/23

Stock Information

Company Name: Genmab A/S
Stock Symbol: GMAB
Market: NASDAQ
Website: genmab.com

Menu

GMAB GMAB Quote GMAB Short GMAB News GMAB Articles GMAB Message Board
Get GMAB Alerts

News, Short Squeeze, Breakout and More Instantly...

GMAB - Expected US Company Earnings on Tuesday, November 7th, 2023

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...

GMAB - Expected earnings - Genmab A/S

Genmab A/S (GMAB) is expected to report $0.34 for Q3 2023

GMAB - Notable earnings before Tuesday's open

2023-11-06 10:30:08 ET Major earnings expected before the bell on Tuesday include: Air Products and Chemicals ( APD ) Datadog ( DDOG ) D.R. Horton ( DHI ) Emerson Electric ( EMR ) Uber Technologies ( UBER ) For further details see: Notable...

GMAB - Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)

Eighteen total abstracts accepted for presentation and publication, including results from four clinical trials evaluating epcoritamab in multiple treatment settings and patient populations Oral presentations highlighting new findings from a clinical trial of epcoritamab in patients with ...

GMAB - Seagen, Genmab update Phase 3 data for uterine cancer therapy

2023-10-23 14:58:57 ET More on Genmab, Seagen, etc. Zai Lab Stock: De-Risking Through Market Tapping Seagen Acquisition By Pfizer: A Strategic Power Move With Potential Windfalls For Investors Genmab Is Down To Attractive Levels Seagen/ Astellas succeed in Ph...

GMAB - TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

TIVDAK demonstrated superior overall survival, progression-free survival and objective response rate compared to chemotherapy in late-breaking results presented at ESMO 2023 congress Results from innovaTV 301 intended to serve as pivotal confirmatory trial for U.S. accelerated approval an...

GMAB - Genmab hits 52-week low after Q3 Darzalex sales

2023-10-18 12:46:20 ET More on Genmab Genmab Is Down To Attractive Levels Genmab A/S (GMAB) Q2 2023 Earnings Call Transcript Seagen, Genmab succeed in Phase 3 trial for cervical cancer therapy Genmab raises FY 2023 guidance on back of Darzalex sales S...

GMAB - Genmab, United Airlines among premarket losers' pack

2023-10-18 08:27:42 ET Nuzee ( NUZE ) -33% on proposed public offering of shares . SciSparc ( SPRC ) -16% . Notable Labs (NTBL) -10% . Genmab ( GMAB ) -9% . Maison Solutions ( MSS ) -8% . Aldeyra Therapeutics ( ALDX ...

GMAB - Johnson & Johnson powers to Q3 beat as pharma outperforms

2023-10-17 07:11:38 ET More on Johnson & Johnson Johnson & Johnson: A Conservative High-Yield Dividend Aristocrat Buy Johnson & Johnson Q3 Earnings Preview: Don't Count On Different Proposition Post Kenvue Spin-Out Johnson & Johnson: The Bull Case Can...

GMAB - Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023

Company Announcement Net sales of DARZALEX ® in the third quarter of 2023 totaled USD 2,499 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; October 17, 2023 – Genmab A/S ...

Previous 10 Next 10